SCHEMBL1063005

SCHEMBL1063005

CCCNC(=O)c1ccccc1C(N)=O

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.66
HTT P42858 1/20 0.66
POLB P06746 2/20 0.55
L3MBTL1 Q9Y468 3/20 0.54
HPGD P15428 4/20 0.53
NAAA Q02083 1/20 0.51
ALDH1A1 P00352 3/20 0.51
GAA P10253 1/20 0.51
KDM4E B2RXH2 2/20 0.50
HCRTR1 O43613 2/20 0.50
HSD17B10 Q99714 1/20 0.50
ADRA1D P25100 1/20 0.49
ADRA1A P35348 1/20 0.49
ADRA1B P35368 1/20 0.49
MAOB P27338 1/20 0.49
THRB P10828 1/20 0.49
RECQL P46063 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5702819 0.90 TSHR (0.83) TSHRHTTL3MBTL1HPGDNAAA
SCHEMBL6903284 0.89 TSHR (0.58) TSHRHTTHPGDALDH1A1KDM4E
SCHEMBL5223903 0.88 TSHR (0.75) TSHRHTTL3MBTL1HPGDNAAA
SCHEMBL29748296 0.87 TSHR (0.73) TSHRHTTL3MBTL1HPGDNAAA
SCHEMBL6565344 0.87 TSHR (0.73) TSHRHTTL3MBTL1HPGDNAAA
SCHEMBL29862779 0.87 TSHR (0.73) TSHRHTTL3MBTL1HPGDNAAA
SCHEMBL2048527 0.87 TSHR (0.73) TSHRHTTL3MBTL1HPGDNAAA
SCHEMBL6565410 0.87 TSHR (0.73) TSHRHTTL3MBTL1HPGDNAAA
SCHEMBL28428107 0.87 TSHR (0.73) TSHRHTTL3MBTL1HPGDNAAA
SCHEMBL28427018 0.87 TSHR (0.73) TSHRHTTL3MBTL1HPGDNAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0854177-B1 Ink compositions XEROX CORP (US) 2004-03-31 EP claimed
CN-116472292-A Modified proteins and protein degrading agents 上海睿跃生物科技有限公司 2023-07-21 CN disclosed
US-8535897-B2 Assays for non-apoptotic cell death and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-09-17 US disclosed
US-20110008803-A1 ASSAYS FOR NON-APOPTOTIC CELL DEATH AND USES THEREOF TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2011-01-13 US disclosed
WO-2009108384-A2 COMPOUNDS AND COMPOSITIONS THAT CAUSE NON-APOPTOTIC CELL DEATH AND USES THEREOF TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2009-09-03 WO disclosed
US-20080299076-A1 Compunds and compositions that cause non-apoptotic cell death and uses thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-04 US disclosed
WO-2007149476-A2 ASSAYS FOR NON-APOPTOTIC CELL DEATH AND USES THEREOF TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2007-12-27 WO disclosed
WO-2002020437-A2 BASIC COMPOUNDS CONTAINING TERTIARY AMIDES WITH ACTIVITY ON TACHYKININ RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM MENARINI RICERCHE S.P.A. (IT) 2002-03-14 WO disclosed
US-4835312-A Production process of N-substituted amide compounds MITSUI CHEMICALS, INCORPORATED (JP) 1989-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080299076-A1 Compunds and compositions that cause non-apoptotic cell death and uses thereof BAD, CASP3, BAX TSHR 4209/4885HTT 1585/4885POLB 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.